Product development pipeline
reSET-O™ for Opioid Use Disorder
Extending Pear's prescription digital therapeutic platform to Opioid Use Disorder (OUD) as an adjunct to outpatient treatment.
reSET-O™ applies the same approach that underpins reSET®: clinically-validated therapy software, prescribed by a clinician, integrated with previously approved pharmaceuticals and established treatment paradigms. In Opioid Use Disorder, that means designing the therapeutic to work alongside medication-assisted treatment and routine outpatient care rather than replacing either.
Integrated with pharmacotherapy
Built to complement clinician-directed medication-assisted treatment for OUD.
Retention and engagement
Structured therapy content and check-ins support patients between clinic visits.
Clinician visibility
Engagement and self-reported data help care teams focus limited visit time.
Regulatory pathway
Pear intends to obtain FDA clearance for reSET-O™ as a prescription therapeutic.
reSET-O™ is part of Pear's product development pipeline. It is not available for prescription until FDA clearance is obtained.